Lynch Regenerative Medicine

What Lynch Regenerative Medicine does

Lynch Regenerative Medicine (LRM) is a Franklin, Tennessee-based regenerative medicine company founded in 2023 that has built a portfolio around recombinant PDGF-BB (platelet-derived growth factor) technology. The platform is anchored by Samuel Lynch, who holds 150+ patents covering PDGF-BB and yeast-based recombinant protein production. LRM operates two subsidiaries: LRM Aesthetics (founded 2023) and LRM Therapeutics (founded 2025). The commercial portfolio comprises three FDA-approved products: REGRANEX (becaplermin gel 0.01%, acquired from Smith+Nephew in 2024) for chronic diabetic foot ulcers; GEM 21S, a dental bone grafting product licensed via an exclusive partnership with Septodont in 2024; and ariessence pure PDGF+, a topical aesthetics product acquired in 2024.

The underlying technology leverages yeast-based recombinant protein manufacturing to produce high-purity PDGF-BB at what the company describes as a cost advantage over mammalian-cell systems. The business model combines direct commercialization (REGRANEX, ariessence) with channel partnerships (Septodont for GEM 21S) across three distinct end markets: chronic wound care, dental bone regeneration, and medical aesthetics. The executive bench is staffed significantly with former Allergan Aesthetics leadership, including Dr. Patti Fanning as Chief Medical Officer, suggesting deliberate commercial scaling in aesthetics.

LRM has raised approximately $22.5M+ in disclosed funding from Champion VC (Fund I and Fund II), with the most recent round closing in Q3 2025. The company operates with 11-50 employees and is positioned as an early-stage (Series A/B-equivalent) platform seeking to scale commercialization across its three approved products while developing additional therapeutic indications through the LRM Therapeutics subsidiary.

Name

Lynch Regenerative Medicine

Legal name

Lynch Regenerative Medicine, LLC

Website

https://lynchregen.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Lynch Regenerative Medicine is a Franklin, TN-based regenerative medicine company (founded 2023) commercializing three FDA-approved PDGF-BB products across wound care, dental bone grafting, and medical aesthetics, built around founder Samuel Lynch's 150+ patent portfolio.

Ownership category

akta.pro rank

Product category

Regenerative Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

akta.pro secondary industries

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Periodontal Regeneration (GTR/EMD/Biologics) (HLABACAI), Hydrating & Barrier Repair Facials (HSALADAD), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Regenerative medicine
• Platelet-derived growth factor
• Wound healing therapeutics
• Periodontal regeneration
• Aesthetic skin rejuvenation

Headquarters

HQ city

Franklin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Others

Revenue model

1. Pharmaceutical Product Sales: LRM generates revenue through the sale of FDA-approved PDGF-based products including REGRANEX (for diabetic foot ulcers), GEM 21S (for periodontal applications), and ariessence pure PDGF+ (for aesthetic applications). The company assumed direct manufacturing and sales of REGRANEX from Smith & Nephew in August 2025.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Lynch Regenerative Medicine develops, manufactures, and commercializes recombinant human platelet-derived growth factor (PDGF-BB) products for wound healing, periodontal regeneration, and aesthetic skin rejuvenation. The company's three FDA-approved products are REGRANEX (becaplermin) gel 0.01% for diabetic foot ulcers, GEM 21S Growth-Factor Enhanced Matrix for dental/periodontal regeneration, and ariessence pure PDGF+ for post-aesthetic procedure skin rejuvenation.

Product overview

Lynch Regenerative Medicine operates as a biopharmaceutical company focused on platelet-derived growth factor (PDGF)-based therapeutics. The company has developed a dual-arm corporate structure with two subsidiaries: LRM Aesthetics, Inc. (focused on the aesthetics/skincare market) and LRM Therapeutics, Inc. (focused on wound care therapeutics). The product portfolio includes three FDA-approved PDGF-based products: ariessence pure PDGF+® (a topical cosmetic for post-aesthetic procedure use), GEM 21S® (a growth-factor enhanced matrix for periodontal/dental regeneration), and REGRANEX® (a gel for diabetic foot ulcers). The company leverages decades of PDGF research pioneered by founder Dr. Samuel Lynch, who holds over 250 publications and patents in the field.

Differentiator

Problem solved

Functional benefit

Brands

• ariessence: Topical cosmetic product brand - ariessence pure PDGF+ for post-procedure skin rejuvenation in aesthetic treatments including microneedling, RF microneedling, laser skin resurfacing, and peels.
• LRM Aesthetics
• LRM Therapeutics

Products and services

• ariessence pure PDGF+ A topical cosmetic product combining platelet-derived growth factor (PDGF) with hyaluronic acid (HA), designed as a post-procedural enhancement for aesthetic treatments including microneedling, RF microneedling, lasers, micro-coring, and chemical peels. Marketed by LRM Aesthetics, Inc. to dermatologists, plastic surgeons, and medical spa providers.
• GEM 21S Growth-Factor Enhanced Matrix An FDA-approved dental regenerative product combining recombinant human platelet-derived growth factor (rhPDGF-BB) with beta tricalcium phosphate (β-TCP) matrix, indicated for treatment of intrabony periodontal defects, furcation defects, and gingival recession associated with periodontal defects. Distributed by Lynch Regenerative Medicine for licensed dentists and periodontists in the US.
• REGRANEX (becaplermin) Gel 0.01% The only FDA-approved recombinant PDGF therapy for treatment of lower extremity diabetic neuropathic ulcers. A gel formulation that initiates wound healing by attracting repair cells to the wound through chemotaxis. Manufactured and sold by LRM Therapeutics, Inc. to wound care specialists, podiatrists, and hospitals.

Quantifiable outcome

• Phase III randomized double-blind placebo-controlled clinical trials demonstrated significant increase in diabetic foot ulcer healing with REGRANEX compared to standard good ulcer care alone.
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Lynch Biologics (Geistlich North America)coreChannel Partner/ Reseller/ Distributor · 25 March 2026LRM entered into a definitive distribution agreement with Lynch Biologics (a Geistlich North America company) to commercialize GEM 21S, an FDA-approved recombinant human platelet-derived growth factor product, for sale to licensed healthcare providers in the United States. GEM 21S is indicated for periodontal regeneration including intrabony defects, furcation defects, and gingival recession. The agreement expands LRM's Pure PDGF portfolio across therapeutic and aesthetic applications, with sales expected to begin Q2 2026.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• SkinMedica (Allergan Aesthetics / AbbVie): Medical aesthetics skincare brand (part of Allergan Aesthetics/AbbVie) offering post-procedure skincare lines. Comparable to LRM Aesthetics' ariessence in the post-aesthetic-procedure skincare category and via shared Allergan alumni leadership.
• Integra LifeSciences: Public medical technology company (IART) with regenerative tissue technologies (Integra Dermal Regeneration Template) and wound care. Comparable as an incumbent regenerative medicine player serving similar surgical and wound healing use cases.
• Smith & Nephew: Global medical device incumbent that previously distributed REGRANEX (now reacquired by LRM). Operates a large Advanced Wound Management portfolio including skin substitutes and negative-pressure wound therapy — overlapping with LRM Therapeutics' market.
• Coloplast: Danish global wound and ostomy care leader offering advanced wound dressings and skin care. Comparable to LRM Therapeutics in the diabetic foot ulcer and chronic wound care end market.
• Stryker (Orthobiologics): Public medical device incumbent with orthobiologics offerings (e.g., bone graft substitutes including historical Augment family). Comparable as a broad incumbent in regenerative orthopedics where PDGF-based therapies have a regulatory history.
• Convatec Group: Public wound care specialist (CTEC) offering advanced dressings, skin substitutes, and devices for chronic wounds including diabetic foot ulcers. Comparable to LRM Therapeutics as a global incumbent in the same end market.

Direct peers

• Organogenesis Holdings: Public regenerative medicine company (ORGO) selling skin substitutes and wound care biologics (e.g., Apligraf, Dermagraft). Directly comparable to LRM Therapeutics in advanced wound care for diabetic foot ulcers and other chronic wounds.
• MiMedx Group: Public company (MDXG) commercializing placental tissue allografts (EpiFix, AmnioFix) for wound care and surgical recovery. Closely comparable to LRM in the regenerative biologic space across wound healing and surgical recovery indications.
• Geistlich Pharma: Swiss dental regeneration specialist whose North American subsidiary Lynch Biologics now distributes GEM 21S for LRM. Directly comparable in dental bone and tissue regeneration, including the Geistlich Bio-Oss and Bio-Gide families.

Emerging players

• Bio-Techne: Public life sciences tools and reagents company (TECH) producing GMP-grade growth factors including recombinant PDGF for research and clinical applications. Comparable as a recombinant growth factor supplier intersecting with PDGF technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lynch-regenerative-medicine
• Instagraminstagram.com/Lynch_Regenerative_Medicine

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lynch Regenerative Medicine